Entera Bio names Organon CMO to its board of directors

Entera Bio Ltd. (NASDAQ: ENTX) announced the appointment of Juan Camilo Arjona Ferreira, M.D., to its board of directors, effective December 1, 2026. Dr. Arjona Ferreira will replace Haya Taitel, who is stepping down from the board.

Dr. Arjona Ferreira currently serves as Head of Research and Development and Chief Medical Officer at Organon & Co. (NYSE: OGN), where he oversees the company's global research and development organization, including early- and late-stage development, regulatory affairs, pharmacovigilance, and medical affairs. Prior to Organon, he held the role of Chief Medical Officer at Myovant Sciences, leading clinical development and medical affairs in women's health and oncology. He also served as Senior Vice President of Clinical Development at Shionogi Inc. and spent more than a decade at Merck & Co., Inc. (NYSE: MRK), where his last position was Executive Director of Clinical Research in Women's Health.

Dr. Arjona Ferreira earned his medical degree and completed OB-GYN specialist training at the Colegio Mayor del Rosario in Bogotá, Colombia, and previously practiced as an obstetrician and gynecologist.

"I am delighted to welcome Juan Camilo to Entera's board," said Miranda Toledano, Chief Executive Officer of Entera, citing his background in late-stage development and regulatory approvals and his focus on women's health conditions.

Entera is a clinical-stage company based in Tel Aviv, Israel, developing oral peptide and protein replacement therapies. Its lead candidate, EB613, is being developed as an oral once-daily tablet for osteoporosis. The company is also developing EB612 as an oral replacement therapy for hypoparathyroidism, with that program set to enter early clinical development.

You May Also Be Interested In

• Femasys adds John Moorhead to its board of directors
• Genworth Financial names new CEO and CFO, effective January 2027
• Palo Alto Networks urges rejection of Tutanota mini-tender offer